公开(公告)号：EP1427720A1

公开(公告)日：2004-06-16

申请号：EP02772871.6

申请日：2002-09-20

申请人： Mitsubishi Pharma Corporation ,  SANOFI-SYNTHELABO

发明人： UEHARA, Fumiaki,MITSUBISHI PHARMA CORPORATION ,  ARITOMO, Keiichi,MITSUBISHI PHARMA CORPORATION ,  SHODA, Aya,MITSUBISHI PHARMA CORPORATION ,  HIKI, Shinsuke,MITSUBISHI PHARMA CORPORATION ,  OKUYAMA, Masahiro,MITSUBISHI PHARMA CORPORATION ,  USUI, Yoshihiro,MITSUBISHI PHARMA CORPORATION ,  OOIZUMI, Mitsuru,MITSUBISHI PHARMA CORPORATION ,  WATANABE, Kazutoshi,MITSUBISHI PHARMA CORPORATION ,  YAMAKOSHI, Koichi,MITSUBISHI PHARMA CORPORATION

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  A61K31/505 ,  A61P25/28

CPC分类号： C07D401/04 ,  C07D239/34 ,  C07D239/47 ,  C07D239/56 ,  C07D401/14 ,  C07D413/14

摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C¿1?-C12 alkyl group which may be substituted; R represents, for example, a group represented by the following formula (II):wherein R?2 and R3¿ independently represent a hydrogen atom or a C¿1?-C8 alkyl group; R?4¿ represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

公开(公告)号：EP1427709A1

公开(公告)日：2004-06-16

申请号：EP02772870.8

申请日：2002-09-20

申请人： Mitsubishi Pharma Corporation ,  SANOFI-SYNTHELABO

发明人： UEHARA, Fumiaki,MITSUBISHI PHARMA CORPORATION ,  ARITOMO, Keiichi,MITSUBISHI PHARMA CORPORATION ,  SHODA, Aya,MITSUBISHI PHARMA CORPORATION ,  HIKI, Shinsuke,MITSUBISHI PHARMA CORPORATION ,  OKUYAMA, Masahiro,MITSUBISHI PHARMA CORPORATION ,  USUI, Yoshihiro,MITSUBISHI PHARMA CORPORATION ,  OOIZUMI, Mitsuru,MITSUBISHI PHARMA CORPORATION ,  WATANABE, Kazutoshi,MITSUBISHI PHARMA CORPORATION

IPC分类号： C07D239/46 ,  C07D239/56 ,  C07D239/34 ,  C07D413/14 ,  C07D401/14 ,  A61K31/505 ,  A61P25/28

CPC分类号： A61K31/535 ,  C07D239/34 ,  C07D239/47 ,  C07D239/56 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14

摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof having inhibitory activity against tau protein kinase 1:wherein R1 represents a C1-C12 alkyl group which may be substituted;R represents, for example, a group represented by the following formula (II):wherein R2 and R3 independently represent a hydrogen atom or a C1-C8 alkyl group; R4 represents a benzene ring which may be substituted, a naphthalene ring which may be substituted, an indan ring which may be substituted, a tetrahydronaphthalene ring which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

摘要翻译： 由式（I）表示的嘧啶酮衍生物或其盐，或其溶剂合物或其水合物对tau蛋白激酶1具有抑制活性：其中R1表示可被取代的C1-C12烷基; R表示例如由下式（II）表示的基团：其中R2和R3独立地表示氢原子或C1-C8烷基; R4表示可被取代的苯环，可被取代的萘环，可被取代的茚满环，可被取代的四氢萘环，或具有1-4个选自下述基团的杂原子的任意取代的杂环 由氧原子，硫原子和氮原子构成，并且总共具有5〜10个构成环的原子。